Search for a command to run...
Hester Biosciences Ltd. demonstrates moderate growth and profitability metrics compared to its peers. While it has a respectable debt-to-equity ratio, it trails behind top performers in revenue growth and efficiency. Value picks are identified among peers with better margins and lower valuation metrics, while several companies exhibit financial weaknesses.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
HESTERBIO | ₹2,037.45 | ₹1,733.23Cr | 54.43 | 9.59% | 0.82 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |